ProfileGDS5678 / 1430224_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 2% 2% 2% 1% 2% 2% 2% 2% 2% 2% 2% 2% 2% 2% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 11.824922
GSM967853U87-EV human glioblastoma xenograft - Control 21.817412
GSM967854U87-EV human glioblastoma xenograft - Control 31.819852
GSM967855U87-EV human glioblastoma xenograft - Control 41.761541
GSM967856U87-EV human glioblastoma xenograft - Control 51.778972
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 11.8472
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 21.82682
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 31.79962
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 41.79592
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 11.814752
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 21.799942
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 31.801682
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 41.809992
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 51.80642